225 related articles for article (PubMed ID: 19267929)
1. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma.
Seniski GG; Camargo AA; Ierardi DF; Ramos EA; Grochoski M; Ribeiro ES; Cavalli IJ; Pedrosa FO; de Souza EM; Zanata SM; Costa FF; Klassen G
BMC Cancer; 2009 Mar; 9():80. PubMed ID: 19267929
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
[TBL] [Abstract][Full Text] [Related]
3. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
[TBL] [Abstract][Full Text] [Related]
4. Methylation biomarkers for pleomorphic lobular breast cancer - a short report.
Moelans CB; Vlug EJ; Ercan C; Bult P; Buerger H; Cserni G; van Diest PJ; Derksen PW
Cell Oncol (Dordr); 2015 Oct; 38(5):397-405. PubMed ID: 26392358
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence.
Carraway HE; Wang S; Blackford A; Guo M; Powers P; Jeter S; Davidson NE; Argani P; Terrell K; Herman JG; Lange JR
Breast Cancer Res Treat; 2009 Mar; 114(2):315-25. PubMed ID: 18404369
[TBL] [Abstract][Full Text] [Related]
7. Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Zargar MA
Asian Pac J Cancer Prev; 2019 Mar; 20(3):839-848. PubMed ID: 30912402
[TBL] [Abstract][Full Text] [Related]
8. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.
Krasteva ME; Bozhanov SS; Antov GG; Gospodinova ZI; Angelov SG
Neoplasma; 2012; 59(1):85-91. PubMed ID: 22103901
[TBL] [Abstract][Full Text] [Related]
10. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.
Zou D; Yoon HS; Perez D; Weeks RJ; Guilford P; Humar B
J Pathol; 2009 Jun; 218(2):265-72. PubMed ID: 19294736
[TBL] [Abstract][Full Text] [Related]
13. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues.
Choi JS; Kim KH; Jeon YK; Kim SH; Jang SG; Ku JL; Park JG
Int J Cancer; 2009 Mar; 124(6):1258-62. PubMed ID: 19089928
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
16. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.
Yari K; Payandeh M; Rahimi Z
Tumour Biol; 2016 Jun; 37(6):8145-52. PubMed ID: 26715274
[TBL] [Abstract][Full Text] [Related]
17. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
18. Impact of RASSF1A gene methylation on clinico-pathological features of tumor and non-tumor tissue of breast cancer.
Gupta V; Agarwal P; Deshpande P
Ann Diagn Pathol; 2021 Jun; 52():151722. PubMed ID: 33621744
[TBL] [Abstract][Full Text] [Related]
19. The expression of ADAM23 and its correlation with promoter methylation in non-small-cell lung carcinoma.
Hu C; Lv H; Pan G; Cao H; Deng Z; Hu C; Wen J; Zhou J
Int J Exp Pathol; 2011 Oct; 92(5):333-9. PubMed ID: 21429053
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
